Evaluation of interleukin-1 and interleukin-6 receptor antagonists in a murine model of acute lung injury.
IL‐1
IL‐6
Kineret
acute respiratory distress syndrome (ARDS)
bleomycin
inflammatory response
receptor antagonists
tocilizumab
Journal
Experimental physiology
ISSN: 1469-445X
Titre abrégé: Exp Physiol
Pays: England
ID NLM: 9002940
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
received:
23
11
2023
accepted:
12
03
2024
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
10
4
2024
Statut:
aheadofprint
Résumé
The acute exudative phase of acute respiratory distress syndrome (ARDS), a severe form of respiratory failure, is characterized by alveolar damage, pulmonary oedema, and an exacerbated inflammatory response. There is no effective treatment for this condition, but based on the major contribution of inflammation, anti-inflammatory strategies have been evaluated in animal models and clinical trials, with conflicting results. In COVID-19 ARDS patients, interleukin (IL)-1 and IL-6 receptor antagonists (IL-1Ra and IL-6Ra, kineret and tocilizumab, respectively) have shown some efficacy. Moreover, we have previously developed novel peptides modulating IL-1R and IL-6R activity (rytvela and HSJ633, respectively) while preserving immune vigilance and cytoprotective pathways. We aimed to assess the efficacy of these novel IL-1Ra and IL-6Ra, compared to commercially available drugs (kineret, tocilizumab) during the exudative phase (day 7) of bleomycin-induced acute lung injury (ALI) in mice. Our results first showed that none of the IL-1Ra and IL-6Ra compounds attenuated bleomycin-induced weight loss and venous
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CIHR
ID : PJT166004
Pays : Canada
Informations de copyright
© 2024 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
Références
Abe, K., Horiguchi, T., Enzan, K., Masaki, Y., Nishikawa, T., & Kimura, T. (2020). Nicorandil, a KATP channel opener, attenuates ischemia‐reperfusion injury in isolated rat lungs. Lung, 198(2), 315–321.
Arni, S., Maeyashiki, T., Latshang, T., Opitz, I., & Inci, I. (2021). Ex vivo lung perfusion with K(ATP) channel modulators antagonize ischemia reperfusion injury. Cells, 10(9), 2296.
Aubin Vega, M., Chupin, C., Massé, C., Dagenais, A., Berthiaume, Y., & Brochiero, E. (2021). Impact of ENaC downregulation in transgenic mice on the outcomes of acute lung injury induced by bleomycin. Experimental Physiology, 106(4), 1110–1119.
Aubin Vega, M., Chupin, C., Pascariu , M., Privé, A., Dagenais, A., Berthiaume, Y., & Brochiero, E. (2019). Dexamethasone fails to improve bleomycin‐induced acute lung injury in mice. Physiological Reports, 7(21), e14253.
Aubin Vega, M., Girault, A., Adam, D., Chebli, J., Privé, A., Maillé, E., Robichaud, A., & Brochiero, E. (2023). Impact of KvLQT1 potassium channel modulation on alveolar fluid homeostasis in an animal model of thiourea‐induced lung edema. Frontiers in Physiology, 13, 2729.
Aubin Vega, M., Girault, A., Meunier, É., Chebli, J., Privé, A., Robichaud, A., Adam, D., & Brochiero, E. (2024). Function of KvLQT1 potassium channels in a mouse model of bleomycin‐induced acute lung injury. Frontiers in Physiology, 15, 1345488. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2024.1345488
Azoulay, E., Lemiale, V., Mourvillier, B., Garrouste‐Orgeas, M., Schwebel, C., Ruckly, S., Argaud, L., Cohen, Y., Souweine, B., Papazian, L., Reignier, J., Marcotte, G., Siami, S., Kallel, H., Darmon, M., & Timsit, J.‐F., & on behalf of the OUTCOMEREA Study Group. (2018). Management and outcomes of acute respiratory distress syndrome patients with and without comorbid conditions. Intensive Care Medicine, 44(7), 1050–1060.
Bardou, O., Privé, A., Migneault, F., Roy‐Camille, K., Dagenais, A., Berthiaume, Y., & Brochiero, E. (2012). K+ channels regulate ENaC expression via changes in promoter activity and control fluid clearance in alveolar epithelial cells. Biochimica et Biophysica Acta, 1818(7), 1682–1690.
Battaglini, D., Fazzini, B., Silva, P. L., Cruz, F. F., Ball, L., Robba, C., Rocco, P. R. M., & Pelosi, P. (2023). Challenges in ARDS definition, management, and identification of effective personalized therapies. Journal of Clinical Medicine, 12(4), 1381.
Bein, T., Briegel, J., & Annane, D. (2016). Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: Yes. Intensive Care Medicine, 42(5), 918–920.
Beitler, J. R., Thompson, B. T., Baron, R. M., Bastarache, J. A., Denlinger, L. C., Esserman, L., Gong, M. N., LaVange, L. M., Lewis, R. J., Marshall, J. C., Martin, T. R., McAuley, D. F., Meyer, N. J., Moss, M., Reineck, L. A., Rubin, E., Schmidt, E. P., Standiford, T. J., Ware, L. B., … Calfee, S. (2022). Advancing precision medicine for acute respiratory distress syndrome. The Lancet Respiratory Medicine, 10(1), 107–120.
Bellani, G., Laffey, J. G., Pham, T., Fan, E., Brochard, L., Esteban, A., Gattinoni, L., van Haren, F., Larsson, A., McAuley, D. F., Ranieri, M., Rubenfeld, G., Thompson, B. T., Wrigge, H., Slutsky, A. S., Pesenti, A., LUNG SAFE Investigators, & ESICM Trials Group. (2016). Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. Journal of the American Medical Association, 315(8), 788–800.
Bihari, S., Bailey, M., & Bersten, A. D. (2016). Steroids in ARDS: To be or not to be. Intensive Care Medicine, 42(5), 931–933.
Bos, L. D., Martin‐Loeches, I., & Schultz, M. J. (2018). ARDS: Challenges in patient care and frontiers in research. European Respiratory Review, 27(147), 170107.
Bos, L. D. J., & Ware, L. B. (2022). Acute respiratory distress syndrome: Causes, pathophysiology, and phenotypes. The Lancet, 400(10358), 1145–1156.
Bosch, N. A., Lee, M.‐M., LeSieur, M. N., Law, A. C., & Walkey, A. J. (2022). Death due to irreversible hypoxemic respiratory failure in ARDSnet clinical trials. Journal of Critical Care, 67, 85–87.
Burger, R. M., Peisach, J., & Horwitz, S. B. (1981). Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. Journal of Biological Chemistry, 256(22), 11636–11644.
Butt, Y., Kurdowska, A., & Allen, T. C. (2016). Acute lung injury: A clinical and molecular review. Archives of Pathology & Laboratory Medicine, 140(4), 345–350.
Calfee, C. S., Janz, D. R., Bernard, G. R., May, A. K., Kangelaris, K. N., Matthay, M. A., & Ware, L. B. (2015). Distinct molecular phenotypes of direct vs indirect ARDS in single‐center and multicenter studies. Chest, 147(6), 1539–1548.
Chen, F., Gong, L., Zhang, L., Wang, H., Qi, X., Wu, X., Xiao, Y., Cai, Y., Liu, L., Li, X., & Ren, J. (2006). Short courses of low dose dexamethasone delay bleomycin‐induced lung fibrosis in rats. European Journal of Pharmacology, 536(3), 287–295.
Chesnutt, A. N., Matthay, M. A., Tibayan, F. A., & Clark, J. G. (1997). Early detection of type III procollagen peptide in acute lung injury: Pathogenetic and prognostic significance. American Journal of Respiratory and Critical Care Medicine, 156(3), 840–845.
Elahi, R., Karami, P., Heidary, A. H., & Esmaeilzadeh, A. (2022). An updated overview of recent advances, challenges, and clinical considerations of IL‐6 signaling blockade in severe coronavirus disease 2019 (COVID‐19). International Immunopharmacology, 105, 108536.
Engel, M., Nowacki, R. M. E., Boden, P., Reiss, L. K., Uhlig, S., Reynaert, N. L., Gopal, P., Wouters, E. F. M., Willems, C. H. M. P., Kloosterboer, N., Wolfs, T. G. A. M., Zimmermann, L. J. I., Vos, G. D., & Kramer, B. W. (2015). The effects of dexamethasone and oxygen in ventilated adult sheep with early phase acute respiratory distress syndrome. Lung, 193(1), 97–103.
Engeroff, P., Belbézier, A., Monsel, A., & Klatzmann, D. (2022). Anakinra reduces lung inflammation in experimental acute lung injury. Immunity, Inflammation and Disease, 10(2), 123–129.
Fadanni, G. P., & Calixto, J. B. (2023). Recent progress and prospects for anti‐cytokine therapy in preclinical and clinical acute lung injury. Cytokine & Growth Factor Reviews, 71–72, 13–25.
Fan, E., Brodie, D., & Slutsky, A. S. (2018). Acute respiratory distress syndrome: Advances in diagnosis and treatment. Journal of the American Medical Association, 319(7), 698–710.
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020). COVID‐19: Immunology and treatment options. Clinical Immunology, 215, 108448.
Fitzgerald, M., McAuley, D. F., & Matthay, M. (2014). Is there a need for emerging drugs for the acute respiratory distress syndrome? Expert Opinion on Emerging Drugs, 19(3), 323–328.
Food and Drug Administration HHS. (2021). Authorizations of emergency use of certain biological products during the COVID‐19 pandemic; availability. Federal Register/Notices, 86(148), 42850–42868.
Food and Drug Administration HHS. (2023). Authorization of Emergency Use of a Drug Product During the COVID‐19 Pandemic; Availability. Federal Register /Notices, 88(48), 15399–15409.
Foster, J. R (2010). Steroids for early acute respiratory distress syndrome: Critical appraisal of Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 2007; 131, 954‐963. Pediatric Critical Care Medicine, 11(3), 404–407.
Frank, J. A., Pittet, J.‐F., Wray, C., & Matthay, M. A. (2008). Protection from experimental ventilator‐induced acute lung injury by IL‐1 receptor blockade. Thorax, 63(2), 147–153.
Gasse, P., Mary, C., Guenon, I., Noulin, N., Charron, S., Schnyder‐Candrian, S., Schnyder, B., Akira, S., Quesniaux, V. F. J., Lagente, V., Ryffel, B., & Couillin, I. (2007). IL‐1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. The Journal of Clinical Investigation, 117(12), 3786–3799.
Gilhodes, J.‐C., Julé, Y., Kreuz, S., Stierstorfer, B., Stiller, D., & Wollin, L. (2017). Quantification of pulmonary fibrosis in a bleomycin mouse model using automated histological image analysis. PLoS ONE, 12(1), e0170561.
Girault, A., & Brochiero, E. (2014). Evidence of K+ channel function in epithelial cell migration, proliferation, and repair. American Journal of Physiology. Cell Physiology, 306(4), C307–C319.
Griffiths, M. J. D., McAuley, D. F., Perkins, G. D., Barrett, N., Blackwood, B., Boyle, A., Chee, N., Connolly, B., Dark, P., Finney, S., Salam, A., Silversides, J., Tarmey, N., Wise, M. P., & Baudouin, S. V. (2019). Guidelines on the management of acute respiratory distress syndrome. British Medical Journal Open Respiratory Research, 6(1), e000420.
Gu, T., Zhao, S., Jin, G., Song, M., Zhi, Y., Zhao, R., Ma, F., Zheng, Y., Wang, K., Liu, H., Xin, M., Han, W., Li, X., Dong, C. D., Liu, K., & Dong, Z. (2021). Cytokine signature induced by SARS‐CoV‐2 spike protein in a mouse model. Frontiers in Immunology, 11, 621441.
Habelrih, T., Tremblay, D.‐É., Di Battista, E., Hou, X., Reuben, A., Ferri, B., Loiselle, S.‐E., Côté, F., Abram, P., Lubell, W. D., Leimert, K. B., Quiniou, C., Girard, S., Olson, D. M., & Chemtob, S. (2023). Pharmacodynamic characterization of rytvela, a novel allosteric anti‐inflammatory therapeutic, to prevent preterm birth and improve fetal and neonatal outcomes. American Journal of Obstetrics and Gynecology, 228(4), 467.e1–467.e16.
He, M., Shi, W., Yu, M., Li, X., Xu, J., Zhu, J., Jin, L., Xie, W., & Kong, H. (2019). Nicorandil attenuates LPS‐induced acute lung injury by pulmonary endothelial cell protection via NF‐κB and MAPK pathways. Oxidative Medicine and Cellular Longevity, 2019, 4957646.
Health Canada. (2022). Regulatory Decision Summary—Actemra. Canada.Ca. https://covid‐vaccine.canada.ca/info/regulatory‐decision‐summary‐detail.html?linkID=RDS01008
Hegeman, M. A., Hennus, M. P., Cobelens, P. M., Kavelaars, A., Jansen, N. J. G., Schultz, M. J., van Vught, A. J., & Heijnen, C. J. (2013). Dexamethasone attenuates VEGF expression and inflammation but not barrier dysfunction in a murine model of ventilator‐induced lung injury. PLoS ONE, 8(2), e57374.
Iglesias‐Julián, E., López‐Veloso, M., de‐la‐Torre‐Ferrera, N., Barraza‐Vengoechea, J. C., Delgado‐López, P. D., Colazo‐Burlato, M., Ubeira‐Iglesias, M., Montero‐Baladía, M., Lorenzo‐Martín, A., Minguito‐de‐la‐Iglesia, J., García‐Muñoz, J. P., Sanllorente‐Sebastián, R., Vicente‐González, B., Alemán‐Alemán, A., & Buzón‐Martín, L. (2020). High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID‐19 patients. Journal of Autoimmunity, 115, 102537.
Jia, Q., Yang, Y., Chen, X., Yao, S., & Hu, Z. (2022). Emerging roles of mechanosensitive ion channels in acute lung injury/acute respiratory distress syndrome. Respiratory Research, 23(1), 366.
Jones, H. D., Crother, T. R., Gonzalez‐Villalobos, R. A., Jupelli, M., Chen, S., Dagvadorj, J., Arditi, M., & Shimada, K. (2014). The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury. American Journal of Respiratory Cell and Molecular Biology, 50(2), 270–280.
Ketcham, S. W., Sedhai, Y. R., Miller, H. C., Bolig, T. C., Ludwig, A., Co, I., Claar, D., McSparron, J. I., Prescott, H. C., & Sjoding, M. W. (2020). Causes and characteristics of death in patients with acute hypoxemic respiratory failure and acute respiratory distress syndrome: A retrospective cohort study. Critical Care, 24(1), 391.
Kimura, D., Saravia, J., Rovnaghi, C. R., Meduri, G. U., Schwingshackl, A., Cormier, S. A., & Anand, K. J. (2016). Plasma biomarker analysis in pediatric ARDS: Generating future framework from a pilot randomized control trial of methylprednisolone: A framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDS. Frontiers in Pediatrics, 4, 31.
Kitzerow, O., Zucker, I. H., Lisco, S. J., & Wang, H.‐J. (2022). Timeline of multi‐organ plasma extravasation after bleomycin‐induced acute lung injury. Frontiers in Physiology, 13, 777072.
Kulkarni, H. S., Lee, J. S., Bastarache, J. A., Kuebler, W. M., Downey, G. P., Albaiceta, G. M., Altemeier, W. A., Artigas, A., Bates, J. H. T., Calfee, C. S., Cruz Dela, C. S., Dickson, R. P., Englert, J. A., Everitt, J. I., Fessler, M. B., Gelman, A. E., Gowdy, K. M., Groshong, S. D., … Matute‐Bello, G. (2022). Update on the features and measurements of experimental acute lung injury in animals: An official American thoracic society workshop report. American Journal of Respiratory Cell and Molecular Biology, 66(2), e1–e14.
Kyriazopoulou, E., Huet, T., Cavalli, G., Gori, A., Kyprianou, M., Pickkers, P., Eugen‐Olsen, J., Clerici, M., Veas, F., Chatellier, G., Kaplanski, G., Netea, M. G., Pontali, E., Gattorno, M., Cauchois, R., Kooistra, E., Kox, M., Bandera, A., Beaussier, H., … Selmi, C. (2021). Effect of anakinra on mortality in patients with COVID‐19: A systematic review and patient‐level meta‐analysis. The Lancet Rheumatology, 3(10), e690–e697.
Leite‐Junior, J. H. P., Garcia, C. S. N. B., Souza‐Fernandes, A. B., Silva, P. L., Ornellas, D. S., Larangeira, A. P., Castro‐Faria‐Neto, H. C., Morales, M. M., Negri, E. M., Capelozzi, V. L., Zin, W. A., Pelosi, P., Bozza, P. T., & Rocco, P. R. M. (2008). Methylprednisolone improves lung mechanics and reduces the inflammatory response in pulmonary but not in extrapulmonary mild acute lung injury in mice. Critical Care Medicine, 36(9), 2621–2628.
Leroy, C., Privé, A., Bourret, J.‐C., Berthiaume, Y., Ferraro, P., & Brochiero, E. (2006). Regulation of ENaC and CFTR expression with K+ channel modulators and effect on fluid absorption across alveolar epithelial cells. American Journal of Physiology‐Lung Cellular and Molecular Physiology, 291(6), L1207–1219.
Lindauer, M. L., Wong, J., Iwakura, Y., & Magun, B. E. (2009). Pulmonary inflammation triggered by ricin toxin requires macrophages and IL‐1 signaling. Journal of Immunology, 183(2), 1419–1426.
Matthay, M. A., Arabi, Y., Arroliga, A. C., Bernard, G., Bersten, A. D., Brochard, L. J., Calfee, C. S., Combes, A., Daniel, B. M., Ferguson, N. D., Gong, M. N., Gotts, J. E., Herridge, M. S., Laffey, J. G., Liu, K. D., Machado, F. R., Martin, T. R., McAuley, D. F., Mercat, A., … Wick, K. D. (2024). A new global definition of acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine, 209(1), 37–47.
Matthay, M. A., Zemans, R. L., Zimmerman, G. A., Arabi, Y. M., Beitler, J. R., Mercat, A., Herridge, M., Randolph, A. G., & Calfee, C. S. (2019). Acute respiratory distress syndrome. Nature Reviews Disease Primers, 5(1), 1.
Matute‐Bello, G., Downey, G., Moore, B. B., Groshong, S. D., Matthay, M. A., Slutsky, A. S., & Kuebler, W. M., & Acute Lung Injury in Animals Study Group. (2011). An official American Thoracic Society workshop report: Features and measurements of experimental acute lung injury in animals. American Journal of Respiratory Cell and Molecular Biology, 44(5), 725–738.
Matute‐Bello, G., Frevert, C. W., & Martin, T. R. (2008). Animal models of acute lung injury. American Journal of Physiology‐Lung Cellular and Molecular Physiology, 295(3), L379–L399.
Meduri, G. U., Bridges, L., Shih, M.‐C., Marik, P. E., Siemieniuk, R. A. C., & Kocak, M. (2016). Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: Analysis of individual patients’ data from four randomized trials and trial‐level meta‐analysis of the updated literature. Intensive Care Medicine, 42(5), 829–840.
Meduri, G. U., & Siemieniuk, R. A. C. (2017). Prolonged glucocorticoid treatment in acute respiratory distress syndrome. Lancet, 389(10078), 1516.
Monahan, L. J. (2013). Acute respiratory distress syndrome. Current Problems in Pediatric and Adolescent Health Care, 43(10), 278–284.
Nadeau‐Vallée, M., Chin, P.‐Y., Belarbi, L., Brien, M.‐È., Pundir, S., Berryer, M. H., Beaudry‐Richard, A., Madaan, A., Sharkey, D. J., Lupien‐Meilleur, A., Hou, X., Quiniou, C., Beaulac, A., Boufaied, I., Boudreault, A., Carbonaro, A., Doan, N.‐D., Joyal, J.‐S., Lubell, W. D., … Chemtob, S. (2017). Antenatal suppression of IL‐1 protects against inflammation‐induced fetal injury and improves neonatal and developmental outcomes in mice. The Journal of Immunology, 198(5), 2047–2062.
Nadeau‐Vallée, M., Quiniou, C., Palacios, J., Hou, X., Erfani, A., Madaan, A., Sanchez, M., Leimert, K., Boudreault, A., Duhamel, F., Rivera, J. C., Zhu, T., Noueihed, B., Robertson, S. A., Ni, X., Olson, D. M., Lubell, W., Girard, S., & Chemtob, S. (2015). Novel noncompetitive IL‐1 receptor‐biased ligand prevents infection‐ and inflammation‐induced preterm birth. The Journal of Immunology, 195(7), 3402–3415.
Pais, F. M., Sinha, P., Liu, K. D., & Matthay, M. A. (2018). Influence of clinical factors and exclusion criteria on mortality in ARDS observational studies and randomized controlled trials. Respiratory Care, 63(8), 1060–1069.
Papazian, L., Aubron, C., Brochard, L., Chiche, J.‐D., Combes, A., Dreyfuss, D., Forel, J.‐M., Guérin, C., Jaber, S., Mekontso‐Dessap, A., Mercat, A., Richard, J.‐C., Roux, D., Vieillard‐Baron, A., & Faure, H. (2019). Formal guidelines: Management of acute respiratory distress syndrome. Annals of Intensive Care, 9(1), 69.
Peng, J., Fu, M., Mei, H., Zheng, H., Liang, G., She, X., Wang, Q., & Liu, W. (2022). Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis. Reviews in Medical Virology, 32(3), e2295.
Quiniou, C., Sapieha, P., Lahaie, I., Hou, X., Brault, S., Beauchamp, M., Leduc, M., Rihakova, L., Joyal, J.‐S., Nadeau, S., Heveker, N., Lubell, W., Sennlaub, F., Gobeil, F., Miller, G., Pshezhetsky, A. V., & Chemtob, S. (2008). Development of a novel noncompetitive antagonist of IL‐1 receptor. The Journal of Immunology, 180(10), 6977–6987.
Ranieri, V. M., Rubenfeld, G. D., Thompson, B. T., Ferguson, N. D., Caldwell, E., Fan, E., Camporota, L., & Slutsky, A. S. (2012). Acute respiratory distress syndrome: The berlin definition. Journal of the American Medical Association, 307(23), 2526–2533.
RECOVERY Collaborative Group. (2021). Tocilizumab in patients admitted to hospital with COVID‐19 (RECOVERY): Preliminary results of a randomised, controlled, open‐label, platform trial. Lancet, 397(10285), 1637–1645.
Reddy, K., Sinha, P., O'Kane, C. M., Gordon, A. C., Calfee, C. S., & McAuley, D. F. (2020). Subphenotypes in critical care: Translation into clinical practice. The Lancet‐Respiratory Medicine, 8(6), 631–643.
Reinert, T., Baldotto, C. S. da R., Nunes, F. A. P., & Scheliga, A. A. de S. (2013). Bleomycin‐induced lung injury. Journal of Cancer Research, 2013, e480608.
Rizzo, A. N., Aggarwal, N. R., Thompson, B. T., & Schmidt, E. P. (2023). Advancing precision medicine for the diagnosis and treatment of acute respiratory distress syndrome. Journal of Clinical Medicine, 12(4), 1563.
Sakuma, T., Takahashi, K., Ohya, N., Nakada, T., & Matthay, M. A. (1998). Effects of ATP‐sensitive potassium channel opener on potassium transport and alveolar fluid clearance in the resected human lung. Pharmacology & Toxicology, 83(1), 16–22.
Sarıoğlu, N., Sunay, F. B., Yay, A., Korkut, O., Erel, F., Hişmioğulları, A. A., Köse, M., & Yalçın, B. (2021). Antiinflammatory effects of adalimumab, tocilizumab, and steroid on lipopolysaccharide‐induced lung injury. Turkish Journal of Medical Sciences, 51(5), 2741–2751.
Sayah, D. N., Zhou, T. E., Omri, S., Mazzaferri, J., Quiniou, C., Wirth, M., Côté, F., Dabouz, R., Desjarlais, M., Costantino, S., & Chemtob, S. (2020). Novel anti‐interleukin‐1β therapy preserves retinal integrity: A longitudinal investigation using OCT imaging and automated retinal segmentation in small rodents. Frontiers in Pharmacology, 11, 296.
Schwingshackl, A., Lopez, B., Teng, B., Luellen, C., Lesage, F., Belperio, J., Olcese, R., & Waters, C. M. (2017). Hyperoxia treatment of TREK‐1/TREK‐2/TRAAK‐deficient mice is associated with a reduction in surfactant proteins. American Journal of Physiology‐Lung Cellular and Molecular Physiology, 313(6), L1030–L1046.
Seam, N., & Suffredini, A. F. (2016). Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: We are not sure. Intensive Care Medicine, 42(5), 924–927.
Shang, W., Zhang, Y., Wang, G., & Han, D. (2023). Anakinra was not associated with lower mortality in hospitalised COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials. Reviews in Medical Virology, 33(2), e2418.
Standiford, T. J., & Ward, P. A. (2016). Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Translational Research, 167(1), 183–191.
Steinberg, K. P., Hudson, L. D., Goodman, R. B., Hough, C. L., Lanken, P. N., Hyzy, R., Thompson, B. T., & Ancukiewicz, M., & National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. (2006). Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. The New England Journal of Medicine, 354(16), 1671–1684.
Sweeney, R. M., & McAuley, D. F. (2017). Prolonged glucocorticoid treatment in acute respiratory distress syndrome—Authors’ reply. Lancet, 389(10078), 1516–1517.
Terzi, F., Demirci, B., Çınar, İ., Alhilal, M., & Erol, H. S. (2022). Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid‐induced ARDS. Respiratory Research, 23(1), 249.
Thompson, B. T., & Ranieri, V. M. (2016). Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: No. Intensive Care Medicine, 42(5), 921–923.
Tom, J., Bao, M., Tsai, L., Qamra, A., Summers, D., Carrasco‐Triguero, M., McBride, J., Rosenberger, C. M., Lin, C. J. F., Stubbings, W., Blyth, K. G., Carratalà, J., François, B., Benfield, T., Haslem, D., Bonfanti, P., van der Leest, C. H., Rohatgi, N., Wiese, L., … Cai, F. (2022). Prognostic and predictive biomarkers in patients with coronavirus disease 2019 treated with Tocilizumab in a randomized controlled trial. Critical Care Medicine, 50(3), 398–409.
Tongyoo, S., Permpikul, C., Mongkolpun, W., Vattanavanit, V., Udompanturak, S., Kocak, M., & Meduri, G. U. (2016). Hydrocortisone treatment in early sepsis‐associated acute respiratory distress syndrome: Results of a randomized controlled trial. Critical Care, 20(1), 329.
Trinh, N. T. N., Privé, A., Kheir, L., Bourret, J.‐C., Hijazi, T., Amraei, M. G., Noël, J., & Brochiero, E. (2007). Involvement of KATP and KvLQT1 K+ channels in EGF‐stimulated alveolar epithelial cell repair processes. American Journal of Physiology‐Lung Cellular and Molecular Physiology, 293(4), L870–L882.
Trinh, N. T. N., Privé, A., Maillé, E., Noël, J., & Brochiero, E. (2008). EGF and K+ channel activity control normal and cystic fibrosis bronchial epithelia repair. American Journal of Physiology‐Lung Cellular and Molecular Physiology, 295(5), L866–L880.
Wang, X., Chen, S., Zhao, L., & Shi, X. (2021). Protective effect of combination of anakinra and MCC950 against acute lung injury is achieved through suppression of the NF‐κB‐mediated‐MAPK and NLRP3‐caspase pathways. International Immunopharmacology, 97, 107506.
Wang, X.‐Q., Zhou, X., Zhou, Y., Rong, L., Gao, L., & Xu, W. (2008). Low‐dose dexamethasone alleviates lipopolysaccharide‐induced acute lung injury in rats and upregulates pulmonary glucocorticoid receptors. Respirology, 13(6), 772–780.
Ware, L. B., & Matthay, M. A. (2000). The acute respiratory distress syndrome. The New England Journal of Medicine, 342(18), 1334–1349.
Wick, K. D., Leligdowicz, A., Zhuo, H., Ware, L. B., & Matthay, M. A. (2021). Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS. JCI Insight, 6(12), e148983.
Xu, H., Sheng, S., Luo, W., Xu, X., & Zhang, Z. (2023). Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup. Frontiers in Immunology, 14, 1277161. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1277161
Xu, T., Qiao, J., Zhao, L., He, G., Li, K., Wang, J., Tian, Y., & Wang, H. (2009). Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 virus in mice. The European Respiratory Journal, 33(4), 852–860.
Yang, Z.‐G., Lei, X.‐L., & Li, X.‐L. (2017). Early application of low‐dose glucocorticoid improves acute respiratory distress syndrome: A meta‐analysis of randomized controlled trials. Experimental and Therapeutic Medicine, 13(4), 1215–1224.
Yehya, N., Servaes, S., Thomas, N. J., Nadkarni, V. M., & Srinivasan, V. (2015). Corticosteroid exposure in pediatric acute respiratory distress syndrome. Intensive Care Medicine, 41(9), 1658–1666.
Yubero, S., Manso, M. A., Ramudo, L., Vicente, S., & De Dios, I. (2012). Dexamethasone down‐regulates the inflammatory mediators but fails to reduce the tissue injury in the lung of acute pancreatitis rat models. Pulmonary Pharmacology & Therapeutics, 25(4), 319–324.
Zhan, P., Lu, X., Li, Z., Wang, W.‐J., Peng, K., Liang, N.‐N., Wang, Y., Li, J., Fu, L., Zhao, H., Xu, D.‐X., & Tan, Z.‐X. (2022). Mitoquinone alleviates bleomycin‐induced acute lung injury via inhibiting mitochondrial ROS‐dependent pulmonary epithelial ferroptosis. International Immunopharmacology, 113(Pt A), 109359.
Zhou, L., Köhncke, C., Hu, Z., Roepke, T. K., & Abbott, G. W. (2019). The KCNE2 potassium channel β subunit is required for normal lung function and resilience to ischemia and reperfusion injury. Federation of American Societies of Experimental Biology Journal, 33(9), 9762–9774.
Zhu, J., Lin, X., Yan, C., Yang, S., & Xu, Z. (2023). Tocilizumab attenuates acute lung injury in rats with sepsis by regulating S100A12/NLRP3. American Journal of Translational Research, 15(1), 99–113.
Zyrianova, T., Lopez, B., Olcese, R., Belperio, J., Waters, C. M., Wong, L., Nguyen, V., Talapaneni, S., & Schwingshackl, A. (2020). K2P2.1 (TREK‐1) potassium channel activation protects against hyperoxia‐induced lung injury. Scientific Reports, 10(1), 22011.